Peroxisome proliferators such as the fibrates act via the peroxisome proliferator activated receptor (PPAR)-α as hypolipidemic agents. Many peroxisome proliferators are also nongenotoxic hepatic carcinogens and hepatotoxicants in rodents. We performed transcription profiling using cDNA microarrays on livers of rats treated for 5 days with 3 doses of the peroxisome proliferator clofibrate. All 3 doses had hepatic effects as assessed by liver to body weight ratio, alanine aminotransferase (ALT) increases and histopathology examination. Analysis of the transcription profiling data identified changes in the expression of many genes within several mechanistic pathways that support existing hypotheses regarding peroxisome proliferator mediated carcinogenicity. Additionally, the transcription profiling, histopathology, and clinical chemistry results suggested a biphasic response to clofibrate. These findings provide insight into the pathogenesis of toxic and carcinogenic effects of clofibrate in rodents and demonstrate the ability of cDNA microarrays to provide information regarding mechanisms of toxicity identified during the drug development process.
Altschul SF, Gish W., Miller W., Myers EW, Lipman DJ (1990). Basic local alignment search tool. J Mol Biol215(3): 403—410.
2.
Ame JC, Rolli V., Schreiber V., Niedergang C., Apiou F., Decker P., Muller S., Hoger T., Menissier-de Murcia J., de Murcia G. (1999). PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem274(25): 17860—17868.
3.
Anderson SP, Cattley RC, Corton JC (1999). Hepatic expression of acute-phase protein genes during carcinogenesis induced by peroxisome proliferators. Mol Carcinog26(4): 226—238.
4.
Ashby J., Brady A., Elcombe CR, Elliott BM, Ishmael J., Odum J., Tugwood JD, Kettle S., Purchase IF (1994). Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol13 Suppl 2: S1—117.
5.
Ayte J., Gil-Gomez G., Haro D., Marrero PF, Hegardt FG (1990). Rat mitochondrial and cytosolic 3-hydroxy-3-methylglutaryl-CoA synthases are encoded by two different genes. Proc Natl Acad Sci USA87(10): 3874— 3878.
6.
Bayly AC, Roberts RA, Dive C. ( 1994). Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol125(1): 197—203.
7.
Belury MA, Moya-Camarena SY, Sun H., Snyder E., Davis JW, Cunningham ML, Van den Heuvel JP (1998). Comparison of dose-response relationships for induction of lipid metabolizing and growth regulatory genes by peroxisome proliferators in rat liver. Toxicol Appl Pharmacol151(2): 254—261.
8.
Bojes HK, Thurman RG (1996). Peroxisome proliferators activate Kupffer cells in vivo. Cancer Res56(1): 1—4.
9.
Bowker-Kinley MM, Davis WI, Wu P., Harris RA, Popov KM (1998). Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex . Biochem J329(Pt 1): 191—196.
10.
Cattley RC, DeLuca J., Elcombe C., Fenner-Crisp P., Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B., Tugwood J., Wahli W. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?Regul Toxicol Pharmacol27(1Pt1): 47—60.
11.
Cherkaoui-Malki M., Meyer K., Cao WQ, Latruffe N., Yeldandi AV, Rao MS, Bradfield CA, Reddy JK (2001). Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis. Gene Expr9(6): 291—304.
Elliott BM, Elcombe CR (1987). Lack of DNA damage or lipid peroxidation measured in vivo in the rat liver following treatment with peroxisomal proliferators . Carcinogenesis8(9): 1213—1218.
14.
Gerbracht U. , Bursch W., Kraus P., Putz B., Reinacher M., Timmermann-Trosiener I., Schulte-Hermann R. (1990). Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis11(4): 617—624.
15.
Gonzalez FJ , Peters JM, Cattley RC (1998). Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst90(22): 1702—1709.
16.
Hegi ME, Ulrich D., Sagelsdorff P., Richter C., Lutz WK ( 1990). No measurable increase in thymidine glycol or 8-hydroxydeoxyguanosine in liver DNA of rats treated with nafenopin or choline-devoid low-methionine diet. Mutat Res238(3): 325—329.
17.
Inestrosa NC , Bronfman M., Leighton F. (1979). Detection of peroxisomal fatty acyl-coenzyme A oxidase activity. Biochem J182(3): 779—788.
18.
Issemann I. , Green S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators . Nature347: 645—650.
19.
James NH, Gill JH, Brindle R., Woodyatt NJ, Macdonald N., Rolfe M., Hasmall SC, Tugwood JD, Holden PR, Roberts RA (1998). Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis . Toxicol Lett102—103: 91— 96.
20.
tJohnson PH, Walker RP, Jones SW, Stevens K., Zajchowski DA, Luke M., Eeckman F., Tan Y., Wong L., Parry G., Morgan TK, Monforte J. (2002). Multiplex gene expression analysis for high throughput drug discovery. Anti-Cancer Drug Design1(14): 1293—1304.
21.
Kasai H., Okada Y., Nishimura S., Rao MS, Reddy JK (1989). Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. Cancer Res49(10): 2603—2605.
22.
Kim I., Kim HG, Kim H., Kim HH, Park SK, Uhm CS, Lee ZH, Koh GY (2000). Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J346 Pt 3: 603—610.
23.
Kraupp-Grasl B., Huber W., Putz B., Gerbracht U., Schulte-Hermann R. (1990 ). Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver. Cancer Res50(12): 3701—3708.
24.
Lambe KG, Woodyatt NJ, Macdonald N., Chevalier S., Roberts RA (1999). Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett110(1—2): 119—127.
25.
Lawrence JW , Wollenberg GK, Frank JD, DeLuca JG (2001). Dexamethasone selectively inhibits WY14,643-induced cell proliferation and not peroxisome proliferation in mice. Toxicol Appl Pharmacol170(2): 113—123.
26.
Lee SS, Pineau T., Drago J., Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H., Gonzalez FJ (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol15(6): 3012—3022.
27.
Marsman DS, Cattley RC, Conway JG, Popp JA ( 1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res48(23): 6739—6744.
28.
Matsubara Y. , Indo Y., Naito E., Ozasa H., Glassberg R., Vockley J., Ikeda Y., Kraus J., Tanaka K. (1989). Molecular cloning and nucleotide sequence of cDNAs encoding the precursors of rat long chain acyl-coenzyme A, short chain acyl-coenzyme A, and isovaleryl-coenzyme A dehydrogenases. Sequence homology of four enzymes of the acyl-CoA dehydrogenase family. J Biol Chem264(27): 16321—16331.
29.
Menegazzi M. , Carcereri-De Prati A., Suzuki H., Shinozuka H., Pibiri M., Piga R., Columbano A., Ledda-Columbano GM (1997). Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of transcription factors NF-kappaB and AP-1 or with expression of tumor necrosis factor alpha. Hepatology25(3): 585— 592.
30.
Moody DE, Reddy JK, Lake BG, Popp JA, Reese DH (1991). Peroxisome proliferation and nongenotoxic carcinogenesis: Commentary on a symposium. Fundam Appl Toxicol16(2): 233—248.
31.
Nemali MR, Usuda N., Reddy MK, Oyasu K., Hashimoto T., Osumi T., Rao MS, Reddy JK (1988). Comparison of constitutive and inducible levels of expression of peroxisomal beta-oxidation and catalase genes in liver and extrahepatic tissues of rat. Cancer Res48(18): 5316—5324.
32.
Nilakantan V., Spear BT, Glauert HP (1998). Effect of the peroxisome proliferator ciprofibrate on lipid peroxidation and 8-hydroxydeoxyguanosine formation in transgenic mice with elevated hepatic catalase activity. Free Radic Biol Med24(9): 1430—1436.
33.
Pani P., Dessi S., Rao KN, Batetta B., Laconi E. (1984). Changes in serum and hepatic cholesterol in lead-induced liver hyperplasia. Toxicol Pathol12: 162—167.
34.
Qu B., Li QT, Wong KP, Ong CN, Halliwell B. (1999). Mitochondrial damage by the “pro-oxidant” peroxisomal proliferator clofibrate. Free Rad Biol Med27(9—10): 1095—1102.
35.
Qu B., Li QT, Wong KP, Tan TM, Halliwell B. (2001). Mechanism of clofibrate hepatotoxicity: Mitochondrial damage and oxidative stress in hepatocytes. Free Rad Biol Med31(5): 659—669.
36.
Reddy JK, Qureshi SA (1979). Tumorigenicity ofthe hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br J Cancer40(3): 476—482.
37.
Reddy JK, Azarnoff DL, Hignite CE (1980). Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature283: 397—398.
38.
Reddy JK, Warren JR, Reddy MK, Lalwani ND (1982). Hepatic and renal effects of peroxisome proliferators: Biological implications. Ann NY Acad Sci386: 81—110.
39.
Reddy JK, Scarpelli DG, Subbarao V., Lalwani ND (1983). Chemical carcinogens without mutagenic activity: Peroxisome proliferators as a prototype. Toxicol Pathol11(2): 172—180.
40.
Rininger JA , Goldsworthy TL, Babish JG (1997). Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats. Carcinogenesis18(5): 935—941.
41.
Roberts RA, Soames AR, Gill JH, James NH, Wheeldon EB (1995). Nongenotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations . Carcinogenesis16(8): 1693—1698.
42.
Roberts RA, James NH, Hasmall SC, Holden PR, Lambe K., Macdonald N., West D., Woodyatt NJ, Whitcome D. (2000). Apoptosis and proliferation in nongenotoxic carcinogenesis: Species differences and role of PPARalpha. Toxicol Lett112—113: 49—57.
43.
Rose ML, Germolec D., Arteel GE, Schoonhoven R., Thurman RG (1997). Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisomeproliferator WY-14,643. Chem Res Toxicol10(10): 1198—1204.
44.
Rose ML, Germolec D., Schoonhoven R., Thurman RG (1997). Kupffer cells are causally responsible for the mitogenic effect ofperoxisome proliferators. Carcinogenesis18(8): 1453—1456.
45.
Rusyn I., Tsukamoto H., Thurman RG (1998). WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. Carcinogenesis19(7): 1217—1222.
46.
Rusyn I., Denissenko MF, Wong VA, Butterworth BE, Cunningham ML, Upton PB, Thurman RG, Swenberg JA (2000). Expression of base excision repair enzymes in rat and mouse liver is induced by peroxisome proliferators and is dependent upon carcinogenic potency. Carcinogenesis21(12): 2141— 2145.
47.
Rusyn I., Kadiiska MB, Dikalova A., Kono H., Yin M., Tsuchiya K., Mason RP, Peters JM, Gonzalez FJ, Segal BH, Holland SM, Thurman RG (2001). Phthalates rapidly increase production of reactive oxygen species in vivo: Role of Kupffer cells. Mol Pharmacol59(4): 744—750.
48.
Schena M., Shalon D., Heller R., Chai A., Brown PO, Davis RW (1996). Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA93(20): 10614—10619.
49.
Schulte-Hermann R. (1979). Adaptive liver growth induced by xenobiotic compounds: Its nature and mechanism. Arch Toxicol Suppl (2): 113—124.
50.
Schulte-Hermann R., Ohde G., Schuppler J., Timmermann-Trosiener I.( 1981). Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin. Cancer Res41(6): 2556—2562.
51.
Tomaszewski KE, Heindel SW, Jenkins WL, Melnick RL (1990). Induction of peroxisomal acyl CoA oxidase activity and lipid peroxidation in primary rat hepatocyte cultures. Toxicology65(1—2): 49—60.
52.
Tugwood JD, Issemann I., Anderson RG, Bundell KR, McPheat WL, Green S. (1992). The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J11(2): 433—439.
53.
Tugwood JD, Aldridge TC, Lambe KG, Macdonald N., Woodyatt NJ (1996). Peroxisome proliferator-activated receptors: Structures and function. Ann NY Acad Sci804: 252—265.
54.
Ward JM, Diwan BA, Ohshima M., Hu H., Schuller HM, Rice JM ( 1986). Tumor-initiating and promoting activities of di(2-ethylhexyl) phthalate in vivo and in vitro. Environ Health Perspect65: 279—291.
55.
Ward JM, Rice JM, Creasia D., Lynch P., Riggs C. (1983). Dissimilar patterns of promotion by di(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice. Carcinogenesis4(8): 1021—1029.
56.
Williams GM , Maruyama H., Tanaka T. (1987). Lack of rapid initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis. Carcinogenesis8(7): 875—880.
